Public Health and Medical Professionals for Transparency Documents
Pfizer’s Documents
Documents with a large file size are provided in a .zip file and will need to be uncompressed after download.
File Name Date Produced File Size Link FDA-CBER-2021-5683-0296904 to -0307543_125742_S1_M5_c4591001-S-D-suppce.zip (xpt) July 1, 2022 1 MB FDA-CBER-2021-5683-0286267 to -0296903_125742_S1_M5_c4591001-S-Supp-D-suppce.zip (xpt) July 1, 2022 2 MB FDA-CBER-2021-5683-0286072 to -0286266_125742_S1_M5_c4591001-S-Supp-D-relrec.zip (xpt) July 1, 2022 54 KB FDA-CBER-2021-5683-0285652 to -0286071_125742_S1_M5_c4591001-S-D-pe.zip (xpt) July 1, 2022 170 KB FDA-CBER-2021-5683-0285644 to -0285651_125742_S1_M5_c4591001-S-D-mo.zip (xpt) July 1, 2022 8 KB FDA-CBER-2021-5683-0282366 to -0285643_125742_S1_M5_c4591001-S-D-mb.zip (xpt) July 1, 2022 2 MB FDA-CBER-2021-5683-0282329 to -0282365_125742_S1_M5_c4591001-S-D-ie.zip (xpt) July 1, 2022 19 KB FDA-CBER-2021-5683-0282130 to -0282328_125742_S1_M5_c4591001-S-D-cm.zip (xpt) July 1, 2022 152 KB FDA-CBER-2021-5683-0225598 to -0282129_125742_S1_M5_c4591001-A-Supp-D-adfacevd.zip (xpt) July 1, 2022 84 MB FDA-CBER-2021-5683-0225100 to -0225597_125742_S1_M5_c4591001-A-D-adcm.zip (xpt) July 1, 2022 1 MB 125742_S2_M1_comvlabp vial puurs.pdf July 1, 2022 648 KB 125742_S2_M1_com195lpus carton puurs.pdf July 1, 2022 691 KB 125742_S2_M1_comvlabkz vial kzoo.pdf July 1, 2022 863 KB 125742_S2_M1_com25ctpus carton puurs.pdf July 1, 2022 672 KB 125742_S2_M1_com195lkz carton kzoo.pdf July 1, 2022 1,024 KB 125742_S2_M1_com25ctkz carton kzoo.pdf July 1, 2022 632 KB 125742_S1_M5_5351_c4591001 interim mth6 sap.pdf July 1, 2022 5 MB 125742_S1_M5_5351_c4591001 interim mth6 protocol deviations.pdf July 1, 2022 2 MB 125742_S1_M5_5351_c4591001 interim mth6 lab measurements sensitive.pdf July 1, 2022 5 MB 125742_S1_M5_5351_c4591001 interim mth6 excluded patients sensitive.pdf July 1, 2022 3 MB 125742_S1_M5_5351_c4591001 interim mth6 excluded patients.pdf July 1, 2022 1 MB 125742_S1_M5_5351_c4591001 interim mth6 errata.pdf July 1, 2022 2 MB 125742_S1_M5_5351_c4591001 interim mth6 efficacy response.pdf July 1, 2022 1 MB 125742_S1_M5_5351_c4591001 interim mth6 discontinued patients.pdf July 1, 2022 4 MB 125742_S1_M5_5351_c4591001 fa interim sap.pdf July 1, 2022 3 MB 125742_S1_M5_5351_c4591001 interim mth6 compliance sensitive.pdf July 1, 2022 1 MB 125742_S2_M1_right of reference.pdf July 1, 2022 2 MB 125742_S2_M1_loa dmf 031786 vials.pdf July 1, 2022 2 MB 125742_S2_M1_loa dmf 012683 vials.pdf July 1, 2022 631 KB 125742_S2_M1_loa dmf 011820 vials.pdf July 1, 2022 616 KB 125742_S2_M1_loa dmf 011793 vials.pdf July 1, 2022 701 KB 125742_S2_M1_loa dmf 011321 vials.pdf July 1, 2022 1,019 KB 125742_S2_M1_hospira diluent label.pdf July 1, 2022 776 KB 125742_S2_M1_loa dmf 10953 stopper.pdf July 1, 2022 861 KB 125742_S2_M1_hospira diluent carton.pdf July 1, 2022 987 KB 125742_S2_M1_fk diluent stamp.pdf July 1, 2022 598 KB 125742_S2_M1_fk diluent carton.pdf July 1, 2022 607 KB 125742_S2_M5_5354_wi235284-protocol.pdf July 1, 2022 16 MB 125742_S1_M5_5351_c4591001-interim-mth6-interlab-standard.pdf July 1, 2022 11 MB 125742_S1_M5_5351_c4591001-fa-interim-narrative-sensitive.pdf July 1, 2022 19 MB 125742_S1_M5_5351_c4591001-interim-mth6-adverse-events.zip (pdf) July 1, 2022 28 MB FDA-CBER-2021-5683-0208521 to -0216666_125742_S1_M5_c4591001-S-Supp-D-suppvs.zip (xpt) June 1, 2022 917 KB FDA-CBER-2021-5683-0205318 to -0208520_125742_S1_M5_c4591001-S-Supp-D-ex.zip (xpt) June 1, 2022 2 MB FDA-CBER-2021-5683-0196049 to -0205317_125742_S1_M5_c4591001-S-Supp-D-ce.zip (xpt) June 1, 2022 8 MB FDA-CBER-2021-5683-0187906 to -0196048_125742_S1_M5_c4591001-S-D-suppvs.zip (xpt) June 1, 2022 915 KB FDA-CBER-2021-5683-0182981 to -0187905_125742_S1_M5_c4591001-S-D-suppmh.zip (xpt) June 1, 2022 616 KB FDA-CBER-2021-5683-0180191 to -0182980_125742_S1_M5_c4591001-S-D-suppis.zip (xpt) June 1, 2022 350 KB FDA-CBER-2021-5683-0178319 to -0180190_125742_S1_M5_c4591001-S-D-suppho.zip (xpt) June 1, 2022 259 KB FDA-CBER-2021-5683-0174607 to -0178318_125742_S1_M5_c4591001-S-D-suppdv.zip (xpt) June 1, 2022 623 KB FDA-CBER-2021-5683-0171524 to -0174606_125742_S1_M5_c4591001-S-D-suppds.zip (xpt) June 1, 2022 405 KB FDA-CBER-2021-5683-0169082 to -0171523_125742_S1_M5_c4591001-S-D-suppdm.zip (xpt) June 1, 2022 334 KB FDA-CBER-2021-5683-0168683 to -0169081_125742_S1_M5_c4591001-S-D-suppcm.zip (xpt) June 1, 2022 71 KB FDA-CBER-2021-5683-0165893 to -0168682_125742_S1_M5_c4591001-S-D-is.zip (xpt) June 1, 2022 1 MB FDA-CBER-2021-5683-0162690 to -0165892_125742_S1_M5_c4591001-S-D-ex.zip (xpt) June 1, 2022 2 MB FDA-CBER-2021-5683-0159487 to -0162689_125742_S1_M5_c4591001-S-D-ec.zip (xpt) June 1, 2022 2 MB FDA-CBER-2021-5683-0158560 to -0159486_125742_S1_M5_c4591001-S-D-dv.zip (xpt) June 1, 2022 558 KB FDA-CBER-2021-5683-0149082 to -0158559_125742_S1_M5_c4591001-S-D-ce.zip (xpt) June 1, 2022 8 MB FDA-CBER-2021-5683-0142307 to -0149081_125742_S1_M5_c4591001-A-Supp-D-adcevd.zip (xpt) June 1, 2022 8 MB 125742_S1_M5_CRF_c4591001 1081 10811194 reissue.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1015 10151238.pdf June 1, 2022 3 MB 125742_S1_M5_CRF_c4591001 1015 10151225.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1015 10151134.pdf June 1, 2022 1 MB STN 125742 0 0 Section 2.5 Clinical Overview reissue.pdf June 1, 2022 5 MB 125742_S1_M5_CRF_c4591001 1128 11281009 reissue.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1015 10151089.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1015 10151047.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1015 10151071.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1015 10151035.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1015 10151011.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131786.pdf June 1, 2022 3 MB 125742_S1_M5_CRF_c4591001 1013 10131718.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1015 10151101.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131658.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131656.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131653.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131554.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1013 10131517.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131255.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131386.pdf June 1, 2022 1,008 KB 125742_S1_M5_CRF_c4591001 1013 10131229.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131699.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1013 10131176.pdf June 1, 2022 3 MB 125742_S1_M5_CRF_c4591001 1013 10131165.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131089.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1013 10131084.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1012 10121112.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1012 10121163.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1011 10111181.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1012 10121097.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1013 10131190.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1009 10091123.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1008 10081667.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1008 10081628.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1011 10111029.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1008 10081603.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1009 10091149.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1009 10091135.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1009 10091128.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1008 10081152.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071443.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1008 10081056.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071441.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071347.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071315.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071306.pdf June 1, 2022 3 MB 125742_S1_M5_CRF_c4591001 1007 10071280.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071276.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071192.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071159.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071124.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071117.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071101.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1007 10071097.pdf June 1, 2022 2 MB 125742_S1_M5_CRF_c4591001 1007 10071050.pdf June 1, 2022 3 MB 125742_S1_M5_CRF_c4591001 1008 10081337.pdf June 1, 2022 1 MB 125742_S1_M5_CRF_c4591001 1008 10081184.pdf June 1, 2022 1 MB 125742_S1_M5_5351_c4591001 interim mth6 publications.pdf June 1, 2022 11 MB 125742_S1_M5_5351_c4591001 interim mth6 patient batches.pdf June 1, 2022 1 MB 125742_S1_M5_5351_c4591001 fa interim protocol deviations sensitive.pdf June 1, 2022 2 MB 125742_S1_M5_5351_c4591001 fa interim discontinued patients.pdf June 1, 2022 3 MB 125742_S1_M5_5351_c4591001 fa interim patient batches.pdf June 1, 2022 1 MB 125742_S1_M5_5351_c4591001 fa interim adverse events.pdf June 1, 2022 32 MB 125742_S1_M5_5314_shi sop 10011.pdf June 1, 2022 2 MB 125742_S1_M2_summary biopharm.pdf June 1, 2022 2 MB 125742_S1_M5_5351_c4591001 interim mth6 randomization.pdf June 1, 2022 1 MB FDA-CBER-2021-5683-0123168-to-0126026_125742_S1_M5_c4591001-A-D-adva.zip (.xpt) May 2, 2022 7 MB FDA-CBER-2021-5683-0066701-to-0123167_125742_S1_M5_c4591001-A-D-adfacevd.zip (.xpt) May 2, 2022 81 MB FDA-CBER-2021-5683-0059000 to -0065773_125742_S1_M5_c4591001-A-D-adcevd.zip (.xpt) May 2, 2022 9 MB FDA CBER 2021 5683 0065774 to 0066700_125742_S1_M5_c4591001 A D addv.xpt May 2, 2022 44 MB FDA CBER 2021 5683 0058955 to 0058999_125742_S1_M5_bnt162 01 S define 2 0 0.xsl May 2, 2022 183 KB FDA CBER 2021 5683 0058795 to 0058828_125742_S1_M5_bnt162 01 A define 2 0 0.xsl May 2, 2022 183 KB FDA CBER 2021 5683 0058829 to 0058954_125742_S1_M5_bnt162 01 S define.xml May 2, 2022 985 KB FDA CBER 2021 5683 0058615 to 0058652_125742_S1_M5_c4591001 S Supp define.xml May 2, 2022 300 KB FDA CBER 2021 5683 0058653 to 0058675_125742_S1_M5_c4591001 S Supp define 2 0 0.xsl May 2, 2022 183 KB FDA CBER 2021 5683 0058676 to 0058794_125742_S1_M5_bnt162 01 A define.xsl May 2, 2022 828 KB FDA CBER 2021 5683 0058595 to 0058614_125742_S1_M5_c4591001 S define 2 0 0.xsl May 2, 2022 183 KB FDA CBER 2021 5683 0058459 to 0058478_125742_S1_M5_c4591001 A Supp define 2 0 0.xsl May 2, 2022 183 KB FDA CBER 2021 5683 0058479 to 0058594_125742_S1_M5_c4591001 S define.xml May 2, 2022 904 KB FDA CBER 2021 5683 0058316 to 0058458_125742_S1_M5_c4591001 A Supp define.xml May 2, 2022 692 KB 125742_S1_M5_CRF_c4591001 1006 10061098.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1006 10061176.pdf May 2, 2022 3 MB 125742_S1_M5_CRF_c4591001 1006 10061094.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1006 10061040.pdf May 2, 2022 4 MB 125742_S1_M5_CRF_c4591001 1006 10061052.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1006 10061020.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1005 10051411.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1005 10051387.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1005 10051293.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1005 10051347.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1005 10051214.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1005 10051054.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1005 10051069.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1003 10031038.pdf May 2, 2022 3 MB 125742_S1_M5_CRF_c4591001 1001 10011100.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1001 10011135.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1001 10011093.pdf May 2, 2022 3 MB 125742_S1_M5_CRF_c4591001 1005 10051047.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1003 10031197.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1003 10031207.pdf May 2, 2022 1 MB 125742_S1_M5_CRF_c4591001 1003 10031186.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1003 10031149.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1003 10031113.pdf May 2, 2022 3 MB 125742_S1_M5_CRF_c4591001 1003 10031111.pdf May 2, 2022 2 MB 125742_S1_M5_CRF_c4591001 1003 10031065.pdf May 2, 2022 3 MB 125742_S1_M5_bnt162 01 S acrf.pdf May 2, 2022 1 MB 125742_S1_M5_bnt162 01 A adrg.pdf May 2, 2022 891 KB 125742_S1_M5_c4591001 S csdrg.pdf May 2, 2022 1 MB 125742_S1_M5_c4591001 S Supp acrf.pdf May 2, 2022 3 MB 125742_S1_M5_c4591001 S acrf.pdf May 2, 2022 3 MB 125742_S1_M5_bnt162 01 S csdrg.pdf May 2, 2022 1 MB 125742_S1_M5_5351_c4591001 interim mth6 sponsor signature.pdf May 2, 2022 12 MB 125742_S1_M5_5351_c4591001 interim mth6 sample crf.pdf May 2, 2022 5 MB 125742_S1_M5_5351_c4591001 interim mth6 randomization sensitive.pdf May 2, 2022 65 MB 125742_S1_M5_5351_bnt162 01 interim3 sample crf.pdf May 2, 2022 9 MB 125742_S1_M5_5351_bnt162 01 interim3 report body.pdf May 2, 2022 42 MB 125742_S1_M5_5351_bnt162 01 interim3 protocol deviations.pdf May 2, 2022 1 MB 125742_S1_M5_5351_bnt162 01 interim3 protocol.pdf May 2, 2022 10 MB 125742_S1_M5_5351_bnt162 01 interim3 patient batches.pdf May 2, 2022 3 MB 125742_S1_M5_5351_bnt162 01 interim3 notes for reader.pdf May 2, 2022 1 MB 125742_S1_M5_5351_bnt162 01 interim3 synopsis.pdf May 2, 2022 4 MB 125742_S1_M5_5351_bnt162 01 interim3 sponsor signature.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01 interim3 sponsor personnel list.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01 interim3 sap.pdf May 2, 2022 3 MB 125742_S1_M5_5351_bnt162 01 interim3 lab measurements.pdf May 2, 2022 91 MB 125742_S1_M5_5351_bnt162 01 interim3 discontinued patients.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01 interim3 demographics.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01 interim3 compliance.pdf May 2, 2022 7 MB 125742_S1_M5_5351_bnt162 01 interim3 adverse events.pdf May 2, 2022 7 MB 125742_S1_M5_5351_bnt162 01 interim3 investigators.pdf May 2, 2022 6 MB 125742_S1_M5_5351_bnt162 01 interim3 invest signature.pdf May 2, 2022 634 KB 125742_S1_M5_5351_bnt162 01 interim3 iec irb.pdf May 2, 2022 1 MB 125742_S1_M5_5351_bnt162 01 interim3 excluded patients.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01_10075.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01_10010.pdf May 2, 2022 1 MB 125742_S1_M5_5351_bnt162 01_20215.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01_20242.pdf May 2, 2022 2 MB 125742_S1_M5_5351_bnt162 01_20116.pdf May 2, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-protocol-deviations.pdf April 1, 2022 1 MB 125742_S1_M5_5351_c4591001-fa-interim-iec-irb-consent-form.pdf April 1, 2022 8 MB 125742_S1_M5_5351_c4591001-fa-interim-invest-signature.pdf April 1, 2022 677 KB 125742_S1_M5_5351_c4591001-fa-interim-demographics.pdf April 1, 2022 28 MB 125742_S1_M5_5351_c4591001-fa-interim-audit-certificates.pdf April 1, 2022 869 KB 125742_S1_M5_5351_c4591001-interim-mth6-invest-signature.pdf April 1, 2022 1 MB reissue_5.3.6 postmarketing experience.pdf April 1, 2022 958 KB 125742_S1_M5_5351_c4591001-interim-mth6-demographics.pdf April 1, 2022 28 MB 125742_S1_M5_5351_c4591001-interim-mth6-audit-certificates.pdf April 1, 2022 1 MB 125742_S1_M5_5351_c4591001-fa-interim-sponsor-signature.pdf April 1, 2022 2 MB 125742_S1_M5_5351_c4591001-interim-mth6-adverse-events-sensitive.pdf April 1, 2022 1 MB 125742_S1_M5_5351_c4591001-fa-interim-sample-crf.pdf April 1, 2022 5 MB 125742_S1_M5_5351_c4591001-fa-interim-randomization-sensitive.pdf April 1, 2022 59 MB 125742_S1_M5_5351_c4591001-fa-interim-randomization.pdf April 1, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-publications.pdf April 1, 2022 10 MB 125742_S1_M1_priority-review-request.pdf March 24, 2022 2 MB FDA-CBER-2021-5683-0023924_125742_S1_M5_c4591001-A-report-cci-chf.xlsx March 1, 2022 10 KB FDA-CBER-2021-5683-0023926_125742_S1_M5_c4591001-A-report-cci-dementia.xlsx March 1, 2022 9 KB FDA-CBER-2021-5683-0023878_125742_S1_M5_c4591001-A-report-cci-aids-hiv.xlsx March 1, 2022 23 KB FDA-CBER-2021-5683-0023895 to -0023915_125742_S1_M5_c4591001-A-report-cci-any-malignancy.xlsx March 1, 2022 35 KB FDA-CBER-2021-5683-0023919 to -0023921_125742_S1_M5_c4591001-A-report-cci-cerebrovascular.xlsx March 1, 2022 12 KB FDA-CBER-2021-5683-0023550 to -0023569_125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.xlsx March 1, 2022 22 KB FDA-CBER-2021-5683-0023711 to -0023875_125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.xlsx March 1, 2022 84 KB FDA-CBER-2021-5683-0023500 to -0023507_125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.xlsx March 1, 2022 29 KB FDA-CBER-2021-5683-0023523 to -0023538_125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.xlsx March 1, 2022 18 KB FDA-CBER-2021-5683-0023540_125742_S1_M5_c4591001-A-comorbidity-categories.xlsx March 1, 2022 19 KB FDA-CBER-2021-5683-0023979 to -0023980_125742_S1_M5_c4591001-A-report-cci-renal.xlsx March 1, 2022 11 KB FDA-CBER-2021-5683-0023983 to -0023984_125742_S1_M5_c4591001-A-report-cci-rheumatic.xlsx March 1, 2022 24 KB FDA-CBER-2021-5683-0023987_125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.xlsx March 1, 2022 21 KB FDA-CBER-2021-5683-0023971 to -0023972_125742_S1_M5_c4591001-A-report-cci-periph-vasc.xlsx March 1, 2022 12 KB FDA-CBER-2021-5683-0023975 to -0023976_125742_S1_M5_c4591001-A-report-cci-pulmonary.xlsx March 1, 2022 12 KB FDA-CBER-2021-5683-0023963_125742_S1_M5_c4591001-A-report-cci-mild-liver.xlsx March 1, 2022 10 KB FDA-CBER-2021-5683-0023965_125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.xlsx March 1, 2022 9 KB FDA-CBER-2021-5683-0023967_125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.xlsx March 1, 2022 9 KB FDA-CBER-2021-5683-0023955 to -0023958_125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.xlsx March 1, 2022 14 KB FDA-CBER-2021-5683-0023960_125742_S1_M5_c4591001-A-report-cci-mi.xlsx March 1, 2022 9 KB FDA-CBER-2021-5683-0023932_125742_S1_M5_c4591001-A-report-cci-hemiplegia.xlsx March 1, 2022 10 KB FDA-CBER-2021-5683-0023936 to -0023937_125742_S1_M5_c4591001-A-report-cci-leukemia.xlsx March 1, 2022 12 KB FDA-CBER-2021-5683-0023944 to -0023950_125742_S1_M5_c4591001-A-report-cci-lymphoma.xlsx March 1, 2022 17 KB FDA-CBER-2021-5683-0023928_125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.xlsx March 1, 2022 9 KB FDA-CBER-2021-5683-0023930_125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.xlsx March 1, 2022 10 KB FDA-CBER-2021-5683-0023455 to -0023486_125742_S1_M5_c4591001-A-define-2-0-0.xsl March 1, 2022 183 KB FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx March 1, 2022 13 KB FDA-CBER-2021-5683-0023490 to -0023491_125742_S1_M5_c4591001-A-bmi-12-15-scale.xlsx March 1, 2022 13 KB FDA-CBER-2021-5683-0022618 to -0022691_125742_S1_M5_c4591001-A-P-adsl-demo-7d-eval-eff-sas.txt March 1, 2022 75 KB FDA-CBER-2021-5683-0023007 to -0023031_125742_S1_M5_c4591001-A-P-adsympt-sas.txt March 1, 2022 43 KB FDA-CBER-2021-5683-0023032 to -0023065_125742_S1_M5_c4591001-A-P-adva-sas.txt March 1, 2022 45 KB FDA-CBER-2021-5683-0022793 to -0022866_125742_S1_M5_c4591001-A-P-adsl-s005-demo-all-p3-saf-sas.txt March 1, 2022 75 KB FDA-CBER-2021-5683-0022867 to -0023006_125742_S1_M5_c4591001-A-P-adsl-sas.txt March 1, 2022 197 KB FDA-CBER-2021-5683-0022692 to -0022765_125742_S1_M5_c4591001-A-P-adsl-demo-7d-wwo-eval-eff-sas.txt March 1, 2022 75 KB FDA-CBER-2021-5683-0022766 to -0022792_125742_S1_M5_c4591001-A-P-adsl-fu-d2-p3-saf-sas.txt March 1, 2022 29 KB FDA-CBER-2021-5683-0022326 to -0022345_125742_S1_M5_c4591001-A-P-adcevd-sas.txt March 1, 2022 27 KB FDA-CBER-2021-5683-0022063 to -0022135_125742_S1_M5_c4591001-A-P-adce-s010-lr-p3-saf-sas.txt March 1, 2022 72 KB FDA-CBER-2021-5683-0022136 to -0022325_125742_S1_M5_c4591001-A-P-adce-s020-se-p3-saf-sas.txt March 1, 2022 193 KB FDA-CBER-2021-5683-0022601 to -0022617_125742_S1_M5_c4591001-A-P-admh-sas.txt March 1, 2022 24 KB FDA-CBER-2021-5683-0022041 to -0022053_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-wo-sg-eval-sas.txt March 1, 2022 19 KB FDA-CBER-2021-5683-0022054 to -0022062_125742_S1_M5_c4591001-A-P-adc19ef-ve-sev-cov-pd1-aai-sas.txt March 1, 2022 12 KB FDA-CBER-2021-5683-0022561 to -0022567_125742_S1_M5_c4591001-A-P-adds-sas.txt March 1, 2022 11 KB FDA-CBER-2021-5683-0022568 to -0022600_125742_S1_M5_c4591001-A-P-adfacevd-sas.txt March 1, 2022 49 KB FDA-CBER-2021-5683-0022346 to -0022364_125742_S1_M5_c4591001-A-P-adcm-sas.txt March 1, 2022 32 KB FDA-CBER-2021-5683-0022365 to -0022560_125742_S1_M5_c4591001-A-P-adds-s002-all-p3-rand-sas.txt March 1, 2022 156 KB 125742_S1_M5_CRF_c4591001-1085-10851216 March 1, 2022 1 MB FDA-CBER-2021-5683-0021981 to -0022027_125742_S1_M5_c4591001-A-P-adc19ef-sas March 1, 2022 81 KB FDA-CBER-2021-5683-0022028 to -0022040_125742_S1_M5_c4591001-A-P-adc19ef-ve-cov-7pd2-sg-eval-sas March 1, 2022 20 KB FDA-CBER-2021-5683-0021930 to -0021943_125742_S1_M5_c4591001-A-P-adae-s092-cr-cut-p3x-saf-sas March 1, 2022 15 KB FDA-CBER-2021-5683-0021944 to -0021963_125742_S1_M5_c4591001-A-P-adae-sas March 1, 2022 35 KB FDA-CBER-2021-5683-0021964 to -0021980_125742_S1_M5_c4591001-A-P-adae-vax-tier2-p3-saf-sas March 1, 2022 18 KB FDA-CBER-2021-5683-0021902 to -0021915_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf2-sas March 1, 2022 15 KB FDA-CBER-2021-5683-0021916 to -0021929_125742_S1_M5_c4591001-A-P-adae-s092-all-unb-p3-saf-sas March 1, 2022 15 KB 125742_S1_M5_CRF_c4591001-1085-10851246.pdf March 1, 2022 1 MB FDA-CBER-2021-5683-0021888 to -0021901_125742_S1_M5_c4591001-A-P-adae-s091-all-pd2-p3-saf1-sas.txt March 1, 2022 14 KB 125742_S1_M5_c4591001-T-S-roadmap.pdf March 1, 2022 703 KB 125742_S1_M5_c4591001-T-S-final-reacto-tables-track.pdf March 1, 2022 2 MB 125742_S1_M5_c4591001-A-report-cci-renal.pdf March 1, 2022 629 KB 125742_S1_M5_c4591001-A-report-cci-rheumatic.pdf March 1, 2022 629 KB 125742_S1_M5_CRF_c4591001-1085-10851129.pdf March 1, 2022 2 MB 125742_S1_M5_CRF_c4591001-1085-10851018.pdf March 1, 2022 2 MB 125742_S1_M5_CRF_c4591001-1085-10851116.pdf March 1, 2022 1 MB 125742_S1_M5_c4591001-T-S-updated-reacto-tlf.pdf March 1, 2022 17 MB 125742_S1_M5_c4591001-T-S-suppl-arg.pdf March 1, 2022 738 KB 125742_S1_M5_c4591001-T-S-summary-differences-csr-vs-update.pdf March 1, 2022 667 KB 125742_S1_M5_c4591001-A-report-cci-lymphoma.pdf March 1, 2022 640 KB 125742_S1_M5_c4591001-A-report-cci-hemiplegia.pdf March 1, 2022 626 KB 125742_S1_M5_c4591001-A-report-cci-leukemia.pdf March 1, 2022 631 KB 125742_S1_M5_c4591001-A-report-cci-periph-vasc.pdf March 1, 2022 632 KB 125742_S1_M5_c4591001-A-report-cci-pulmonary.pdf March 1, 2022 630 KB 125742_S1_M5_c4591001-A-report-cci-peptic-ulcer.pdf March 1, 2022 625 KB 125742_S1_M5_c4591001-A-report-cci-mild-liver.pdf March 1, 2022 628 KB 125742_S1_M5_c4591001-A-report-cci-mod-sev-liver.pdf March 1, 2022 626 KB 125742_S1_M5_c4591001-A-report-cci-metastatic-tumour.pdf March 1, 2022 636 KB 125742_S1_M5_c4591001-A-report-cci-mi.pdf March 1, 2022 624 KB 125742_S1_M5_c4591001-A-report-cci-any-malignancy.pdf March 1, 2022 670 KB 125742_S1_M5_c4591001-A-newlist-c4591001-6k-participants-enrolled-v3-17sep2020.pdf March 1, 2022 846 KB 125742_S1_M5_c4591001-A-report-cci-aids-hiv.pdf March 1, 2022 629 KB 125742_S1_M5_c4591001-A-first-c4591001-360-participants-enrolled-v1-13aug20-update.pdf March 1, 2022 607 KB 125742_S1_M5_c4591001-A-report-cci-diabetes-without-comp.pdf March 1, 2022 627 KB 125742_S1_M5_c4591001-A-comorbidity-categories.pdf March 1, 2022 637 KB 125742_S1_M5_c4591001-A-report-cci-diabetes-with-comp.pdf March 1, 2022 626 KB 125742_S1_M5_c4591001-A-report-cci-chf.pdf March 1, 2022 628 KB 125742_S1_M5_c4591001-A-report-cci-dementia.pdf March 1, 2022 626 KB 125742_S1_M5_c4591001-A-report-cci-cerebrovascular.pdf March 1, 2022 632 KB 125742_S1_M5_5351_c4591001-fa-interim-oversight-committees.pdf March 1, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-lab-measurements-sensitive.pdf March 1, 2022 5 MB 125742_S1_M5_c4591001-A-c4591001-subject-list-for-12-25-immuno-analysis-27jan2021.pdf March 1, 2022 620 KB 125742_S1_M5_c4591001-A-c4591001-phase-1-subjects-from-dmw.pdf March 1, 2022 634 KB 125742_S1_M5_c4591001-A-adrg.pdf March 1, 2022 2 MB 125742_S1_M5_c4591001-A-bmi-12-15-scale.pdf March 1, 2022 627 KB 125742_S1_M5_5351_c4591001-interim-mth6-protocol.pdf March 1, 2022 37 MB 125742_S1_M5_c4591001-A-201114-hiv-preferred-terms.pdf March 1, 2022 602 KB 125742_S1_M5_5351_c4591001-interim-mth6-oversight-committees.pdf March 1, 2022 13 MB 125742_S1_M5_5351_c4591001-fa-interim-protocol.pdf March 1, 2022 31 MB 125742_S1_M5_5351_c4591001-fa-interim-excluded-patients.pdf March 1, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-errata.pdf March 1, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-efficacy-response.pdf March 1, 2022 2 MB 125742_S1_M5_5351_c4591001-fa-interim-compliance-sensitive.pdf March 1, 2022 1 MB 125742_S1_M5_5351_c4591001-ad-hoc-label-tables.pdf March 1, 2022 889 KB 125742_S1_M5_5351_c4591001-fa-interim-compliance.pdf March 1, 2022 2 MB 125742_S1_M4_4223_R-20-0072.pdf March 1, 2022 5 MB 125742_S1_M4_4223_185350.pdf March 1, 2022 1 MB 125742_S1_M5_5351_c4591001-fa-interim-lab-measurements.pdf March 1, 2022 12 MB 125742_S1_M5_5351_c4591001-fa-interim-excluded-patients-sensitive.pdf March 1, 2022 16 MB 125742_S1_M2_26_pharmkin-written-summary.pdf March 1, 2022 1 MB 125742_S1_M2_24_nonclinical-overview.pdf March 1, 2022 2 MB 125742_S1_M2_26_pharmkin-tabulated-summary.pdf March 1, 2022 1 MB 125742_S1_M2_22_introduction.pdf March 1, 2022 670 KB 125742_S1_M1_waiver-req-designated-suffix.pdf March 1, 2022 3 MB 125742_S1_M1_us-agent-authorization.pdf March 1, 2022 1 MB 125742_S1_M1_userfee.pdf March 1, 2022 628 KB 125742_S1_M2_27_synopses-indiv-studies.pdf March 1, 2022 2 MB 125742_S1_M1_trans-of-oblig.pdf March 1, 2022 717 KB 125742_S1_M2_27_literature-references.pdf March 1, 2022 2 MB 125742_S1_M1_ipsp-agreed-letter.pdf March 1, 2022 658 KB 125742_S1_M1_financial-cert-3454.pdf March 1, 2022 3 MB 125742_S1_M1_financial-cert-bias.pdf March 1, 2022 696 KB 125742_S1_M1_fast-track-designation.pdf March 1, 2022 649 KB 125742_S1_M1_exclusivity-claim.pdf March 1, 2022 616 KB 125742_S1_M1_cover.pdf March 1, 2022 1 MB 125742_S1_M1_debarment.pdf March 1, 2022 656 KB 125742_S1_M1_3674.pdf March 1, 2022 5 MB 125742_S1_M1_356h.pdf March 1, 2022 714 KB 125742_S1_M1_priority-review-request.pdf March 1, 2022 2 MB CRFs for site 1128.pdf January 31, 2022 14 MB CRFs for site 1096.pdf January 18, 2022 11 MB CRFs for site 1081.pdf December 30, 2021 13 MB Supplemental Index 12-22-21.pdf December 22, 2021 2 MB STN 125742_0_0 Section 2.7.4 summary-clin-safety.pdf December 13, 2021 6 MB STN 125742_0_0 Section 2.7.3 Summary of Clinical Efficacy.pdf December 13, 2021 3 MB STN 125742_0_0 Section 2.5 Clinical Overview.pdf December 13, 2021 4 MB CRFs for site 1055.pdf December 13, 2021 6 MB BATES-FDA-CBER-2021-5683-0002376_relrec.xpt December 13, 2021 567 KB BATES-FDA-CBER-2021-5683-0002380_ti.xpt December 13, 2021 37 KB BATES-FDA-CBER-2021-5683-0002379_te.xpt December 13, 2021 3 KB BATES-FDA-CBER-2021-5683-0002378_ta.xpt December 13, 2021 8 KB signed F21-5683 CBER Dec 13 2021 Response Letter.pdf December 13, 2021 207 KB BATES-FDA-CBER-2021-5683-0002377_supppr.xpt December 13, 2021 72 KB BATES-FDA-CBER-2021-5683-0002375_addv-sas.txt December 13, 2021 5 KB BATES-FDA-CBER-2021-5683-0002374_adc19ef-ve-sev-cov-7pd2-wo-eval-sas.txt December 13, 2021 9 KB BATES-FDA-CBER-2021-5683-0002373_adc19ef-ve-sev-cov-7pd2-eval-sas.txt December 13, 2021 9 KB BATES-FDA-CBER-2021-5683-0002372_adc19ef-ve-cov-7pd2-eval-sas.txt December 13, 2021 9 KB Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part B.pdf December 1, 2021 14 MB Pages 42-289-Section 5.2 – listing-clinical-sites-cvs_Part A.pdf December 1, 2021 12 MB 5.2 listing of clinical sites and cvs pages 1-41.pdf November 17, 2021 8 MB 5.2 tabular listing.pdf November 17, 2021 2 MB 5.3.6 postmarketing experience.pdf November 17, 2021 984 KB BATES-93_tv.xpt November 17, 2021 16 KB BATES-92_adc19ef-ve-cov-7pd2-wo-eval-sas.txt November 17, 2021 9 KB